Search Results - Tremblay G

US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma by Dolph M, Tremblay G, Leong H

Connect to this object online.

Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States by Ramjee L, Vurgun N, Ngai C, Patel M, Tremblay G

Connect to this object online.

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea by Tremblay G, Majethia U, Breeze JL, Kontoudis I, Park J

Connect to this object online.

Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory... by Tremblay G, Livings C, Crowe L, Kapetanakis V, Briggs A

Connect to this object online.

Systematic review of health state utility values for acute myeloid leukemia by Forsythe A, Brandt PS, Dolph M, Patel S, Rabe APJ, Tremblay G

Connect to this object online.

Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia by Tremblay G, Dolph M, Bhor M, Said Q, Elliott B, Briggs A

Connect to this object online.

Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness usi... by Tremblay G, Westley T, Cappelleri JC, Arondekar B, Chan G, Bell TJ, Briggs A

Connect to this object online.

Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States by Tremblay G, Said Q, Roy AN, Cai B, Ashton Garib S, Hearnden J, Forsythe A

Connect to this object online.

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia by Tremblay G, Dolph M, Bhor M, Said Q, Roy A, Elliott B, Briggs A

Connect to this object online.